Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Charity says Scottish men being left without important treatment option after SMC decision

A charity and medical experts are calling for the Scottish Medicines Consortium (SMC) to justify why it has decided not to recommend the use of XTANDI (enzalutamide) to treat adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy, in whom chemotherapy is not yet clinically indicated.

A charity and medical experts are calling for the Scottish Medicines Consortium (SMC) to justify why it has decided not to recommend the use of XTANDI (enzalutamide) to treat adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy, in whom chemotherapy is not yet clinically indicated. Manufacturer Astellas is “perplexed” that the SMC has not recommended enzalutamide despite meeting End of Life criteria and demonstrating cost-effectiveness within previously accepted thresholds for such treatment. Scientists behind the drug that during the process all questions were adequately addressed around the cost-effectiveness

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy